Where can researchers source third-party tested DSIP?

Midwest Peptide supplies research-grade DSIP with a Certificate of Analysis included for every batch, validated by HPLC purity and mass spectrometry identity testing.

Age Verification

You must be 21 years or older to access this website. All products are for research use only.

Are you 21 years of age or older?

By entering, you confirm that you are at least 21 years old and agree to our terms of service.

Memorial Day: 15% off code MEMDAY15Memorial Day Sale — 15% off site-wide with code MEMDAY15

Free shipping on every orderFree shipping on every order

5% off with Zelle or Apple CashSave an extra 5% when you pay with Zelle or Apple Cash

Bulk pricing discounts up to 18%Bulk pricing discounts up to 18% off

DSIP Discovery: 1977 Swiss Research | Midwest Peptide

DSIP and Sleep Architecture: EEG Research in Animal ModelsPrev|Delta Sleep-Inducing Peptide (DSIP) in Research: A Literature ReviewNext

DSIP Discovery: The 1977 Swiss Research and Nonapeptide Chemistry

DSIP · Published April 9, 2026 · Updated May 18, 2026 · 8 min read

Quick Answer

DSIP was discovered in 1977 by Swiss researchers Schoenenberger and Monnier as a nonapeptide isolated from rabbit cerebral venous blood during slow-wave sleep induction. This article covers the original isolation, sequence determination, and chemistry that established DSIP as a research peptide. For research use only, not for human consumption.

DSIP Discovery: The 1977 Swiss Research and Nonapeptide Chemistry

Research Use Only. All products are strictly for research use only (RUO). Not for human consumption. Products on this site are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. By purchasing, you agree that you are a qualified researcher and that products will be used solely for in-vitro research purposes.

The 1977 Swiss Research
Nonapeptide Chemistry
DSIP Tissue Distribution
Conservation Across Species
DSIP and Other Sleep-Related Peptides
Subsequent Research Following the Original Discovery
Open Research Questions
Conclusion
Related Research Articles
Explore Related Products
Frequently Asked Questions
Glossary

DSIP discovery research provides the historical and biochemical foundation for understanding DSIP as a research tool. The peptide was identified in 1977 by Swiss researchers studying sleep-active substances using cerebral venous blood from rabbits during slow-wave sleep induction. The discovery was a significant advance in sleep biology research because it established a specific molecular candidate for endogenous sleep regulation. As the discovery and chemistry component of the DSIP research cluster, this article reviews the published literature on the discovery of DSIP and on the structural chemistry of the nonapeptide.

Frequently Asked Questions

What is DSIP in research contexts?

DSIP (Delta Sleep-Inducing Peptide) is a synthetic nonapeptide first identified from cerebral venous blood of rabbits in 1977. It is studied in preclinical models for its effects on sleep architecture, the HPA axis, and neuroprotection.

How was DSIP originally discovered?

DSIP was identified in 1977 by Schoenenberger and Monnier in Switzerland, isolated from the cerebral venous blood of rabbits in delta wave (slow-wave) sleep. The peptide was named for its association with delta sleep induction in early bioassays.

What is the chemical structure of DSIP?

DSIP is a nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. It is highly conserved across mammalian species and is widely distributed in brain tissue, peripheral organs, and even plant material.

Is DSIP approved for human use?

No. DSIP is not approved by the FDA for any human therapeutic use. It is supplied strictly for in-vitro and preclinical research purposes by qualified investigators.

Glossary

Key terms used in this article.

Nonapeptide: A peptide consisting of nine amino acid residues; DSIP has the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu.
Slow-Wave Sleep (SWS): The deepest stage of non-REM sleep, characterized by high-amplitude, low-frequency delta waves on EEG.
HPA Axis: The hypothalamic-pituitary-adrenal axis, a neuroendocrine system regulating the stress response via CRH, ACTH, and glucocorticoids.
ACTH: Adrenocorticotropic hormone, secreted by the anterior pituitary in response to CRH and stimulating glucocorticoid release from the adrenal cortex.
Schoenenberger and Monnier: The Swiss researchers who first isolated and characterized DSIP from rabbit cerebral venous blood in 1977.
Delta Wave: Low-frequency, high-amplitude EEG waves characteristic of slow-wave sleep.

More from the Blog

Continue exploring research insights and updates.

Subcutaneous vs Intranasal: Choosing an Administration Route for DSIP, Selank, and Kisspeptin in Research

Subcutaneous vs intranasal administration for CNS-targeted research peptides: how to choose between routes for DSIP, Selank, and Kisspeptin based on molecular size, brain access, pharmacokinetics, and the published literature.

May 5, 2026

Can I Still Buy Compounded Tirzepatide? (2026 Research Context)

FDA restricted compounded tirzepatide for human use when the shortage ended. The Research Use Only research peptide channel for tirzepatide (GLP-2 TZ) operates under entirely separate regulations.

May 5, 2026

For Research Use Only. DSIP is intended exclusively for in vitro and preclinical research. It is not approved for human use, is not a drug, and should never be administered to humans or to animals outside of an authorized research protocol.

The 1977 Swiss Research

The discovery of DSIP traces back to research at the University of Bern, Switzerland, in the 1970s. The Swiss research group was led by Marcel Monnier, a Swiss neurophysiologist who had been studying sleep biology and the molecular mechanisms underlying sleep induction. Monnier and colleagues had developed a research approach using electrical stimulation of brain regions known to induce slow-wave sleep, then collecting cerebral venous blood from these animals to test for sleep-active substances.

The research methodology was conceptually elegant. The hypothesis was that during slow-wave sleep induction, the brain would release into the venous outflow molecules that mediate the sleep state. By collecting this venous blood and testing it for activity in recipient animals, the research could potentially identify molecular candidates for endogenous sleep regulation.

Through years of work, the Monnier group succeeded in isolating from the cerebral venous blood a peptide fraction that produced sleep-inducing effects when injected into recipient animals. The active substance was characterized as a small peptide and eventually identified as a nonapeptide with specific amino acid sequence. The 1977 publication established this peptide as a defined chemical entity and named it Delta Sleep-Inducing Peptide (DSIP) based on its effects on delta-wave (slow-wave) sleep.

The Swiss research was a major contribution to sleep biology because it identified one of the first specific peptide candidates for endogenous sleep regulation. The discovery motivated subsequent research on the molecular biology of sleep and on the broader role of neuropeptides in sleep-wake regulation.

Nonapeptide Chemistry

DSIP is a nonapeptide consisting of nine amino acids with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (or W-A-G-G-D-A-S-G-E in single letter code). The chemical formula is C₃₅H₄₉N₁₁O₁₅ with a molecular weight of approximately 849 g/mol. The peptide has a relatively simple chemical structure that is amenable to chemical synthesis and characterization.

The amino acid sequence of DSIP includes both polar and nonpolar residues, with the tryptophan at the N-terminus providing a chromophore that has been useful for analytical characterization of the peptide. The aspartate and glutamate residues provide acidic groups that contribute to the peptide's chemical properties, while the glycine residues provide flexibility in the peptide backbone.

The relatively simple structure of DSIP makes it amenable to standard solid-phase peptide synthesis methods, and synthetic DSIP has been the form most commonly used in subsequent research. The synthetic approach provides several advantages over the original isolation approach, including consistent purity, reliable supply, and the ability to produce specific quantities for research applications.

The chemical characterization of DSIP since its original isolation has supported subsequent research by providing the foundational understanding of the peptide's structure and properties. The accumulated chemistry research provides the basis for using DSIP as a research tool in modern preclinical investigations.

DSIP Tissue Distribution

Following the original discovery, subsequent research characterized the tissue distribution of endogenous DSIP in research animals. The peptide has been found in the hypothalamus, pituitary gland, limbic system, and several peripheral tissues, with the central nervous system being the major site of expression and biological activity.

The hypothalamic expression of DSIP is consistent with its role as a sleep-regulating neuropeptide, since the hypothalamus contains many of the neural circuits involved in sleep-wake regulation. The presence of DSIP in this brain region supports the hypothesis that it functions as an endogenous sleep regulator in research models.

The pituitary expression of DSIP suggests connections to neuroendocrine biology, particularly to the hypothalamic-pituitary-adrenal (HPA) axis that regulates stress responses. The dual expression in hypothalamus and pituitary places DSIP at the intersection of sleep regulation and neuroendocrine biology, providing the molecular basis for its dual functions in these research areas.

The peripheral tissue expression of DSIP includes various other tissues that contribute to integrated DSIP biology. The breadth of tissue expression supports the description of DSIP as a multifunctional neuropeptide rather than as a sleep-specific molecule.

Conservation Across Species

DSIP is conserved across multiple mammalian species, with the same nonapeptide sequence found in rabbits, rodents, and various other research animals. This evolutionary conservation supports the conclusion that DSIP has fundamental biological functions that have been preserved through mammalian evolution.

The cross-species conservation of DSIP has practical implications for research because findings in one research animal species can generally be extended to other species. The accumulated research on DSIP across multiple species provides a more comprehensive picture of its biology than would be available from research in any single species.

The evolutionary conservation also supports the conclusion that DSIP is not an artifact of any single research model but rather a real biological molecule with conserved functions. This is one of the more important findings from the broader DSIP research literature.

DSIP is one of several peptides that have been identified as candidates for endogenous sleep regulation in research models. Other sleep-related peptides include various hypocretins/orexins, melatonin (a non-peptide molecule but with similar regulatory functions), and various other neuropeptides studied in sleep biology research.

The relationship between DSIP and other sleep-related molecules provides context for understanding the integrated regulation of sleep in research models. Sleep regulation involves multiple molecular components working together, and DSIP is one specific example of a peptide that participates in this integrated regulation.

The discovery of DSIP through direct sleep biology research distinguishes it from many other neuropeptides that were identified through other research approaches. The unique discovery history makes DSIP a particularly interesting research tool for sleep biology applications.

Subsequent Research Following the Original Discovery

The 1977 discovery of DSIP motivated subsequent research that extended the characterization of the peptide beyond its original sleep-inducing effects. Research groups in multiple countries have studied DSIP for effects on stress response biology, neuroendocrine regulation, neuroprotection, and various other research areas.

The accumulated research literature spans approximately five decades and provides a substantial foundation for understanding DSIP as a research tool. The breadth of research applications reflects the multiple biological functions of DSIP and the broad relevance of the peptide to multiple research areas.

The continued research on DSIP since its discovery reflects ongoing interest in this neuropeptide as a research tool. The unique discovery history, the conservation across species, the multiple research applications, and the relatively simple chemical structure all combine to make DSIP a useful research compound for various neuropeptide research questions.

Open Research Questions

Several open research questions remain in the DSIP discovery research literature. These include the identification of specific receptors that mediate DSIP biological effects in research models, the characterization of how DSIP is regulated and produced in vivo in research animals, and how the original sleep-inducing effects observed in the Swiss research relate to the broader biological functions characterized in subsequent research. Each of these is a legitimate research opportunity for investigators studying neuropeptide biology.

Conclusion

DSIP discovery research provides the historical and biochemical foundation for understanding DSIP as a research tool. The 1977 Swiss research that identified DSIP from cerebral venous blood, the nonapeptide chemistry of the molecule, the cross-species conservation, and the subsequent research extending the characterization all combine to position DSIP as a unique and well characterized research compound. For investigators using DSIP as a research tool, the discovery and chemistry literature provides essential context for understanding the molecule.

For more on the full DSIP research cluster, see the pillar overview article and the supporting articles on each major topic.

DSIP is supplied by Midwest Peptide for research use only and is not intended for human administration.

Explore more peer-reviewed research and laboratory guides from our science team:

All products are third-party tested with a Certificate of Analysis (COA) included. For research use only.

DSIP, 99%+ purity, COA included
Selank 10mg, 99%+ purity, COA included
Semax 10mg, 99%+ purity, COA included

Browse All Research Peptides →

Age Verification

DSIP Discovery: The 1977 Swiss Research and Nonapeptide Chemistry